Cooley, Wilson Sonsini Steer Neurocrine's $2.9B Soleno Buy
Neurocrine Biosciences has agreed to acquire biotechnology company Soleno Therapeutics for about $2.9 billion in cash, in a deal advised by Cooley LLP and Wilson Sonsini Goodrich & Rosati PC, the...To view the full article, register now.
Already a subscriber? Click here to view full article